Ionis Pharmaceuticals Enters Collaboration Agreement with Janssen Biotech

San Diego – January 29, 2015 – Cooley advised Ionis Pharmaceuticals Inc. on a global collaboration, option and license agreement with Janssen Biotech Inc. to discover and develop antisense drugs to treat autoimmune disorders of the GI tract.

Pursuant to the agreement, Ionis will receive $35 million in up-front payments for three programs, including a payment to initiate human lead optimization on the first collaboration target. Isis is also eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for the programs.

Ionis is the leader in antisense drug discovery and development, exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.

Partner Jane Adams, a member of Cooley's life sciences partnering and licensing group, led the Cooley team that advised Ionis Pharmaceuticals on the collaboration.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.